EXPERIMENTAL GASTRITIS IN MICE ENHANCES ANXIETY IN A GENDER-RELATED MANNER


*Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Universitätsplatz 4, A-8010 Graz, Austria
**Molecular and Clinical Psychobiology, Department of Psychiatry and Psychotherapy, University of Würzburg, Füchsleinstrasse 15, D-97080 Würzburg, Germany

Abbreviations: ANOVA, analysis of variance; EDTA, ethylenediamine tetraacetate; EPMT, elevated plus-maze test; HPA, hypothalamic–pituitary–adrenal; HSD, honestly significant difference; IBD, inflammatory bowel disease; MPO, myeloperoxidase; SIHT, stress-induced hyperthermia test; SPECT, single photon emission computed tomography; TST, tail suspension test; Tr., baseline rectal temperature.

Population-based surveys show that a history of gastroenteritis as well as neurotic and psychiatric disorders is a risk factor for developing pain-related (functional) bowel disorders such as functional dyspepsia and irritable bowel syndrome (Spiller, 2003). Accordingly, there is a considerable comorbidity of inflammatory bowel disease (IBD) and pain-related bowel disturbances with anxiety, depression, somatization and other psychiatric disorders (Wilhelmsen et al., 1995; Mayer et al., 2001a; Whitehead et al., 2002; Dunlop et al., 2003; Pace et al., 2003; North et al., 2004; Mawdsley and Rampton, 2005). Pain-related bowel disorders are hypothesized to arise from a disturbance in the bidirectional interactions between the gut and the brain. On the one hand, sensitization of afferent pathways from the gut to the brain is thought to contribute to pain and hyperalgesia (Mayer and Collins, 2002; Mulak and Bonaz, 2004). On the other hand, psychic stress has a negative influence on IBD and can trigger or exacerbate symptoms of pain-related bowel disorders (Mayer et al., 2001b; Mittermaier et al., 2004; Murray et al., 2004; Taché and Perdue, 2004; Wong and Chang, 2004). Stress activates the emotional motor system which includes the hypothalamic–pituitary–adrenal axis (HPA) as well as the sympathetic and parasympathetic nervous system, and these outputs are thought to disturb bowel function (Schwetz et al., 2003; Million and Taché, 2004).

This concept is supported by experimental findings that exposure to stress alters gut function and aggravates experimental colitis (Stam et al., 1997; Million et al., 1999; Taché and Perdue, 2004; Mayer and Collins, 2002; Milde et al., 2005; Reber et al., 2006). In addition, there is emerging evidence that pain-related (functional) bowel disorders and IBD share common mechanisms (Bradesi et al., 2003; Talley, 2006) and that anxiety and depression are factors relevant to both disease entities (Whitehead et al., 2002;
Bradesi et al., 2003; Dunlop et al., 2003; Pace et al., 2003; Mittermaier et al., 2004; North et al., 2004; Mawdsley and Rampton, 2005; Talley, 2006). Thus, depression induced by neonatal maternal separation enhances the vulnerability of adult mice to intestinal inflammation (Varghese et al., 2006) and anxiety induced by intra-amygdaloid administration of corticosterone leads to mechanical hypersensitivity of the rat colon (Myers et al., 2005).

Since it has not yet been explored whether experimentally induced gastrointestinal inflammation leads to alterations of affective behavior, the first and major aim of this study was to examine whether induction of gastritis in mice would increase anxiety- and/or depression-related behavior. To induce gastritis, iodoacetamide was added to the drinking water at a concentration of 0.1% for 7 days, which has previously been shown to elicit gastritis (Piqueras et al., 2003; Holzer et al., 2007) and induce gastric hypersensitivity to distension and acid exposure (Ozaki et al., 2002; Lamb et al., 2003). Since pain-related bowel disorders, particularly irritable bowel syndrome, have a considerably higher prevalence in women than in men (Strid et al., 2001; Chang and Heitkemper, 2002; Taché et al., 2005), the second aim was to test both male and female mice in order to reveal any gender difference in the possible impact of gastric inflammation on affective behavior. The third aim was to assess whether anxiety-like behavior and circulating corticosterone vary with the estrous cycle. Anxiety-related behavior was assessed with the elevated plus-maze test (EPMT; Pellow and File, 1986; Belzung and Griebel, 2001) and stress-induced hyperthermia test (SIHT; Zethof et al., 1994; Olivier et al., 2003) while depression-like behavior was evaluated with the tail suspension test (TST; Steru et al., 1985; Liu and Gershonfeld, 2001; Cryan et al., 2005). Plasma levels of corticosterone were determined to obtain a measure of HPA axis activity. The fourth aim was to characterize iodoacetamide-induced gastritis in terms of gastrointestinal mucosal damage, gastric myeloperoxidase (MPO) activity and diurnal home-cage activity, drinking and feeding. The fifth and last aim was to address the question of whether iodoacetamide may enter the brain to influence emotional behavior by a central site of action.

**EXPERIMENTAL PROCEDURES**

**Experimental animals**

This study was carried out with adult male and female mice of the outbred strain Hi:m:OF1 (Division of Laboratory Animal Science and Genetics, Department of Biomedical Research, Medical University of Vienna, Himberg, Austria). At the time of the experiments they were 8–16 weeks old and weighed 25–35 g. The animals were housed in groups of three to five per cage under controlled temperature (22±1 °C), relative air humidity (50±15%) and light conditions (lights on at 06:00 h, lights off at 18:00 h, maximal intensity 150 lux). All experiments were approved by an ethical committee at the Federal Ministry of Education, Science and Culture of the Republic of Austria and conducted according to the Directive of the European Communities Council of 24 November 1986 (86/609/EEC). The experiments were designed in such a way that the number of animals used and their suffering were minimized.

**Experimental protocols**

Six experimental studies were performed. Study 1 took 2 weeks to complete and was carried out with two groups of male and two groups of female mice, each group comprising six to seven animals. In week 1 all mice drank normal tap water. In week 2, one group of male and one group of female mice continued to receive normal tap water, whereas the other two groups of animals received tap water containing 0.1% (w/v) iodoacetamide (Sigma, Vienna, Austria) to induce gastritis. Since iodoacetamide is light-sensitive, the iodoacetamide-containing drinking water was made up fresh every day. At the end of week 2, i.e. at experimental day 15, trunk blood and gastric tissue were collected for the determination of circulating corticosterone and MPO activity in the gastric wall.

Study 2 took 18 days to complete and was performed with two groups of male and two groups of female mice, each group comprising 10–11 animals. As in study 1, all mice drank normal tap water during week 1. In week 2, one group of male and one group of female mice continued to receive normal tap water, whereas the other two animal groups received tap water containing 0.1% iodoacetamide to induce gastritis. In week 3 a sequence of behavioral tests was carried out while the mice continued to drink either tap water (controls) or tap water containing iodoacetamide. On day 15 the animals were subjected to the EPMT, followed by the SIHT on day 16. On day 18 the TST was performed, 45 min after which trunk blood and gastric tissue were collected for the assay of circulating corticosterone and gastric MPO activity. The stress-induced hyperthermia was tested between 13:00 h and 13:30 h, the EPMT and TST were carried out between 10:00 h and 14:00 h, while blood plasma and gastric tissue were collected between 11:00 h and 14:00 h.

In addition, the fluid intake per cage (populated by three or four mice) was determined. To this end, the water bottles were refilled every day between 08:30 h and 09:00 h with 150 ml tap water with or without iodoacetamide, and the weight of the water bottles was recorded at the beginning and end of each 24 h period. The drinking volume was expressed as ml/g body weight which was determined on experimental days 1, 8 and 16 and used for calculation of the drinking volume (ml/g body weight) during experimental days 1–7, 8–14 and 15–18, respectively.

Study 3 was carried out to characterize diurnal home-cage activity, drinking and feeding as well as body weight during treatment of female mice with iodoacetamide for 7 days. To this end, six female mice were placed singly in six cages of the LabMaster system (TSE Systems, Bad Homburg, Germany). After 1 week of adaptation in the cages during which the mice drank normal tap water, iodoacetamide (0.1%) was added to the drinking water, and home-cage activity, drinking and feeding were recorded continuously for a second week. The body weight was determined once daily between 09:00 h and 09:30 h during which the content of the drinking bottles was renewed.

In study 4 we examined whether treatment of mice with iodoacetamide for 1 week causes gastrointestinal mucosal damage at the macroscopic and histological level. Two groups of five female mice were used in these experiments. As in study 1, all mice drank normal tap water during week 1. During week 2, one group of mice continued to receive normal tap water, whereas the other group received tap water containing 0.1% iodoacetamide. The macroscopic and histological appearance of the gastric, jejunal and colonic mucosa was examined on day 15.

Study 5 was performed to assess whether the estrous cycle affects anxiety and circulating corticosterone. For this purpose, a total of 30 female mice were used and divided into six groups of five mice, each group being housed in a single cage. After adaptation in the cages for 2 weeks, group 1 was subjected to the...
tetramethylbenzidine (Merck, Darmstadt, Germany) in the enzyme assay was based on the MPO-catalyzed oxidation of the primary granules of the neutrophils (Krawisz et al., 1984). The 3.72 g/l EDTA (Roth, Karlsruhe, Germany) and 5 g/l hexadecyltriton X-100 (Sigma-Aldrich, Steinheim, Germany) were recorded and collected for determining the stress-induced rise of circulating corticosterone. All experiments of study 5 took place between 09:00 and 11:00 h. In study 5 the distribution of iodoacetamide labeled with $^{125}$I in the body of two mice was examined through single photon emission computed tomography (SPECT) and ex vivo measurement of radioactivity levels in the blood and brain.

Circulating corticosterone

In order to obtain trunk blood, the animals were deeply anesthetized with ketamine (150 mg/kg intraperitoneally) and decapitated. Both trunk blood and tail blood were collected into vials coated with EDTA (Greiner, Kremsmünster, Austria) kept on ice. Following centrifugation for 20 min at 4 °C and 1200 × g, blood plasma was collected and stored at −20 °C until assay. The plasma levels of corticosterone were determined with an enzyme immunoassay kit (Assay Designs, Ann Arbor, MI, USA). According to the manufacturer's specifications, the sensitivity of the assay is 27 pg/ml, and the intra- and inter-assay coefficient of variation amounts to 7.7 and 9.7%, respectively.

MPO activity

The enzyme activity of MPO (donor:H$_2$O$_2$ oxidoreductase, EC 1.11.1.7) was determined according to previously described spectrophotometric techniques (Suzuki et al., 1983; Krawisz et al., 1984; Graff et al., 1998). At autopsy, full-thickness pieces of the gastric corpus (120–160 mg) were excised, shock-frozen in liquid nitrogen and stored at −70 °C until assay. After homogenization in potassium phosphate buffer (0.05 M) of pH 7.4 and centrifugation at 40,000 × g at 4 °C for 20 min, the pellets were taken up in potassium phosphate buffer (0.05 M) of pH 6.0 containing 3.72 g/l EDTA (Roth, Karlsruhe, Germany) and 5 g/l hexadecyltrimethylammonium bromide (Sigma) which releases MPO from the primary granules of the neutrophils (Krawisz et al., 1984). The enzyme assay was based on the MPO-catalyzed oxidation of tetramethylbenzidine (Merck, Darmstadt, Germany) in the presence of H$_2$O$_2$ (Suzuki et al., 1983). The absorbance of the samples was measured at 655 nm.

MPO activity was expressed relative to the MPO activity of human neutrophils. To this end, a sample of human neutrophils (5 million cells in 2 ml of 0.05 M potassium phosphate buffer of pH = 7.4) was extracted in an identical manner as the tissue samples and assayed as described above. A standard curve was constructed by measuring the absorbance of the reaction mixture with various dilutions of the neutrophil extract. Since the MPO activity in the gastric tissue samples was determined as an index of neutrophil infiltration, the MPO activity of the tissue extracts was expressed as human neutrophil equivalents/mg wet tissue.

Macrosopic and histological injury to the mucosa

The stomach, jejunum, ileum, proximal colon and distal colon were pinned flat on a silicon elastomer-coated plate and examined for macroscopically visible damage. Immediately afterward, specimens of the gastric corpus, jejunum, ileum, proximal colon and distal colon were taken in a standardized manner from the same region in each animal and fixed in a medium containing 2% paraformaldehyde, 2.5% glutaraldehyde and 0.1 M cacodylate buffer of pH 7.4 and embedded in Technovit 7100 (Heraeus Kulzer, Wehrheim, Germany). Then 2.5 μm sections were cut, stained with a mixture of Methylene Blue–Azure II and Basic Fuchsins (Holzer et al., 2007) and examined under a light microscope for the presence of structural damage in the mucosa.

Distribution of $^{125}$I-iodoacetamide in the mouse body

Mice were anesthetized by an i.p. injection of tribromoethanol (Avertin®; Sigma-Aldrich, Steinheim, Germany; 250 mg/kg). Five minutes after injection of $^{125}$I-iodoacetamide (approximately 37 MBq in 0.1 ml) into the tail vein, small animal SPECT images were acquired over a period of 30 min with a multipinhole collimator mounted on an Ecam Signature® single head camera (Siemens, Erlangen, Germany). Three-dimensional images were reconstructed with a dedicated multipinhole software (HiSPECT®™, Scivis, Göttingen, Germany). One hour post-injection the animals were decapitated, blood and the brain were collected in vials and radioactivity was measured with a gamma counter.

Determination of estrous cycle phase

Vaginal smears were collected with cotton-tipped swabs and transferred to a drop of physiological saline (NaCl, 0.9%) on glass slides. After staining with a drop of thionine acetate (0.5%), the vaginal smears were examined under a light microscope. Four phases of the estrous cycle (estrus, metestrus, diestrus and proestrus) were differentiated on the basis of the number and morphology of the cells in the vaginal fluid (Frick et al., 2000).

Behavioral tests

Prior to all behavioral tests, the mice were allowed to adapt to the test room (22±1 °C, 50±15% relative air humidity, lights on at 06:00 h, lights off at 18:00 h, maximal light intensity 100 lux) for at least 2 days.

EPM Test

The animals were placed in the center of a maze with four arms arranged in the shape of a plus (Pellow and File, 1986; Belzung and Griebel, 2001). Specifically, the maze consisted of a central quadrangle (5×5 cm), two opposing open arms (30 cm long, 5 cm wide) and two opposing closed arms of the same size but equipped with 15 cm high walls at their sides and the far end. The device was made of opaque gray plastic and elevated 70 cm above the floor. The light intensity at the center quadrangle was 70 lux, on the open arms 80 lux and in the closed arms 40 lux.

At the beginning of each trial, the animals were placed on the central quadrangle facing an open arm. The movements of the animals during a 5 min test period were tracked by a video camera positioned above the center of the maze and recorded with the software Videomot2 (TSE Systems). Post-test this software was used to evaluate the animal tracks and to determine the number of their entries into the open arms, the time spent on the open arms and the total distance traveled in the open and closed arms during the test session. Entry into an arm was defined as the instance when the mouse placed its four paws on that arm.

SIHT

Measurement of the basal temperature in mice with a rectal probe represents a stressor that causes an increase in the temperature by about 1–1.5 °C within 15 min (Zethof et al., 1994; Olivier et al.,...
The circadian pattern of home-cage activity, drinking and feeding was recorded with a six cage LabMaster system (TSE Systems). Each cage was fitted with a highly sensitive feeding and drinking sensor and a photo-beam-based activity monitoring system that recorded every ambulatory movement (Theander-Carrillo et al., 2006). Animal location in the horizontal plane was detected with infrared sensor pairs arranged in strips. The sensors for detection of movement operated efficiently in both light and dark phases. All parameters were measured continuously and simultaneously and analyzed with a custom-made software.

Statistics
Statistical evaluation of the results was performed on SPSS 11.5 (SPSS Inc., Chicago, IL, USA) with two-way analysis of variance (ANOVA) to identify gender differences, treatment effects and interactions between these factors. The homogeneity of variance was analyzed with the Levene test. Since there is evidence that visceral pain behavior in rodents is subject to gender differences (Taché et al., 2005), planned comparisons (Kirk, 1995) regarding gender differences within treatments were made with Dunn’s (Bonferroni) comparison test. For post hoc analysis of group differences the Tukey HSD (honestly significant difference) test was employed.

The direction and strength of the relationship between estrous cycle phase and anxiety as well as circulating corticosterone were evaluated with Spearman’s rank correlation technique. Differences between two independent groups of data were analyzed with the two sample t-test. The data obtained with the LabMaster system were evaluated on SigmaStat (Systat Inc., San Jose, CA, USA) with ANOVA for repeated measures followed by the Holm-Sidak test. Probability values of \( P < 0.05 \) were regarded as statistically significant. All data are presented as means±S.E.M., \( n \) referring to the number of mice in each group unless stated otherwise.

Results

Effect of iodoacetamide treatment on body weight

Mice treated with oral iodoacetamide for 1 week appeared healthy and did not exhibit any overt sign of sickness. The body weight of male and female mice, determined per cage with three or four mice, differed throughout the experiment (Fig. 1A, B). Animals that drank normal tap water during the whole experiment gained in body weight throughout the 18 day observation period independently of their gender (Fig. 1A). Specifically, male mice gained 0.58±0.43 g (\( n = 5 \)) and female mice 1.20±0.15 g (\( n = 3 \)) during the period of 8–18 days. Female mice treated with iodoacetamide from day 8 onwards exhibited a very small increase in body weight between days 8 and 18 (0.12±0.34 g, \( n = 3 \)), whereas male mice exhibited a minor loss of body weight (−0.97±0.61 g, \( n = 5 \)) during that period (Fig. 1B). Because body weight was determined per cage (\( n = 3–5 \)) with three or four animals, the number of observations was too small for ANOVA.

Effect of iodoacetamide treatment on drinking volume

During the first week of observation the daily fluid intake, calculated per cage with three or four mice and expressed as ml per g body weight, was nominally higher in male than in female control mice, but this gender difference was no longer evident during the second and third weeks of observation (Fig. 2A). The drinking volume fell by some 50% when male and female mice were forced to drink water containing iodoacetamide from day 8 onwards. This effect of iodoacetamide was sustained throughout the observation period up to day 18 although some tendency toward recovery was observed in male mice (Fig. 2B). Because the drinking volume was determined per cage (\( n = 3–5 \)) with three or four animals, these data could be subjected to descriptive statistics only.

Effect of iodoacetamide on circadian home-cage activity, drinking and feeding

Analysis of the circadian activity pattern revealed that iodoacetamide reduced drinking, feeding and home-cage activity, these changes reaching statistical significance only during the dark phase (Fig. 3B, C, D). While the decrease in nocturnal drinking and locomotor activity was maintained throughout the 7 day period of iodoacetamide treatment, nocturnal feeding returned to normal values from day 5 onwards. There was also an initial decrease in body weight, which reached statistical significance during days 1 and 2, while from day 3 onwards body weight returned to levels measured before iodoacetamide treatment (Fig. 3A).
Effect of iodoacetamide treatment on gastric MPO activity

MPO activity determined at day 15 was significantly elevated (ANOVA for factor treatment: \( F_{(2,21)} = 62.25, P < 0.01 \)) in iodoacetamide-treated mice as compared with control animals (Fig. 4A). In addition, the iodoacetamide-induced increase in MPO activity was significantly greater in female than in male mice (ANOVA for factor gender: \( F_{(1,21)} = 17.96, P < 0.01 \)), whereas in mice drinking normal tap water (Fig. 4B).

![Graphs showing body weight and drinking volume](image)

**Fig. 1.** Body weight (g) of male and female mice, assessed on days 1, 8 and 18 during the course of the experiments. Control mice (A) continued to drink normal tap water during the treatment period whereas the experimental group (B) received tap water containing iodoacetamide (0.1%). The values represent means ± S.E.M.

**Fig. 2.** Daily water intake (ml/g body weight) of male and female mice, averaged for the experimental days 1–7, 8–14 and 15–18 during the course of the experiments. Control mice (A) continued to drink normal tap water during the treatment period whereas the experimental group (B) received tap water containing iodoacetamide (0.1%). The values represent means ± S.E.M.
The gastric MPO levels did not exhibit any significant gender difference (Fig. 4A). The interaction between the factors treatment and gender was also significant ($F_{(1,21)}=7.95$, $P=0.01$). The effect of iodoacetamide to enhance gastric MPO activity was still evident at day 18 when the behavioral tests had been completed (ANOVA for factor treatment: $F_{(2,30)}=13.53$, $P<0.01$; Fig. 4B). Furthermore, at this time point any gender difference had disappeared as the gastric MPO activity in iodoacetamide-treated female mice had become significantly lower ($t_{(12)}=3.42$) than at day 15 (Fig. 4A, B). In contrast, gastric MPO activity in control animals was nominally higher at day 18 than at day 15, although this change was statistically not significant (Fig. 4A, B).

Fig. 3. Body weight (A) and circadian pattern of home-cage activity (B), drinking (C) and feeding (D) before and during a 1 week period of iodoacetamide treatment (0.1% added to the drinking water) on days 1–7. The white stripes depict the light phase, and the gray stripes the dark phase. The parameters are presented as a percentage of the values recorded on day 0 (A) or during the dark phase of day 0 (B–D). The values represent means±S.E.M., $n=6$. * $P<0.05$ versus respective values recorded on day 0 (A) or during the dark phase of day 0 (B–D).
Effect of iodoacetamide on the macroscopic and histological appearance of the gastric and colonic mucosa

On macroscopic inspection, the gastric, jejunal and colonic mucosa did not differ between mice that had drunk normal tap water (control) or tap water containing iodoacetamide (0.1%) from experimental day 8 onwards. MPO activity was expressed as human neutrophil equivalents/mg wet tissue. The values represent means±S.E.M., n as indicated in brackets. * P<0.05, ** P<0.01 versus control mice of the same gender and analysis day; *+ P<0.01 versus male iodoacetamide-treated mice analyzed on day 15; ** P<0.01 versus female iodoacetamide-treated mice analyzed on day 15.

Effect of iodoacetamide on circulating corticosterone

Treatment with iodoacetamide caused a significant reduction of the circulating corticosterone levels as measured on day 15 (ANOVA for factor treatment: $F_{(1,22)}=5.38$, $P<0.05$). Planned comparison revealed that the plasma corticosterone concentration fell only in female ($t_{(15)}=-2.87$, iodoacetamide-treated: $t_{(16)}=-3.80$) and female (control: $t_{(11.03)}=-2.53$, iodoacetamide-treated: $t_{(12.35)}=-5.36$) mice were higher than at day 15 but did not display any treatment or gender difference (Fig. 6B).

Distribution of iodoacetamide in the brain

Five minutes after i.v. injection of $^{123}$I-iodoacetamide to two anesthetized mice, small animal SPECT images were acquired over a period of 30 min. As shown in Fig. 7, no focal or generalized uptake of $^{123}$I-iodoacetamide into the brain could be visualized by SPECT (Fig. 7). The radioactivity measured in the brain was in general lower than the background activity observed in the periphery. One hour post-injection, the levels of radioactivity per g blood and brain were determined and expressed as a percentage of the radioactivity administered to the animals. The radioactivity in the blood was found to be 19.1 and 21.0 times higher than that in the brain.

Effect of iodoacetamide treatment on anxiety-related behavior

The anxiety-related behavior was assessed with the EPMT and SIHT. In the EPMT, the number of entries into the open arms and the time spent on the open arms were taken as indices of anxiety. These parameters were ex-
pressed as a percentage of the total entries into and the total time spent on any arm during the 5 min test session. Planned comparison revealed that, in particular, female control mice spent significantly more time ($t_{(18)} = -3.13$) on the open arms than male control mice (Fig. 8A). Furthermore, it was found that iodoacetamide treatment significantly reduced the time that female mice spent on the open arms ($t_{(18)} = 2.26$) but had no effect on male mice (Fig. 8A). As a result, following iodoacetamide treatment male and female mice no longer differed in the duration of open arm exploration. Further analysis of the anxiety-related behavior on the EPMT demonstrated that iodoacetamide treatment reduced the number of entries into the open arms (ANOVA for factor treatment: $F_{(1,37)} = 4.34$, $P < 0.05$). In the post hoc analysis it was found that the number of open arm entries was significantly decreased only in female, but not male iodoacetamide-treated mice ($t_{(18)} = 2.89$), while male and female control mice did not differ in this parameter (Fig. 8B).

In order to obtain a measure of overall locomotor activity, the total distance traveled in the open and closed arms during the 5 min test session was calculated. Female control mice traveled a nominally longer distance than male control mice, and iodoacetamide treatment led to a nominal reduction of the total traveling distance in male and female mice (Fig. 8C), but neither difference reached statistical significance.

ANOVA of the $T_1$ measured in the SIHT showed that this parameter was gender-dependent ($F_{(1,37)} = 56.72$, $P < 0.01$) and that there was an interaction between gender and iodoacetamide treatment ($F_{(1,37)} = 25.93$, $P < 0.01$). In the post hoc analysis, $T_1$ in male control mice turned out to be significantly lower than in female control mice (Tukey HSD test: $P < 0.01$; Fig. 9A). Following iodoacetamide treatment, $T_1$ significantly decreased in female mice (Tukey HSD test: $P < 0.01$) and significantly increased in male mice (Tukey HSD test: $P < 0.01$; Fig. 9A). As a
consequence, T1 of iodoacetamide-treated mice was no longer subject to any gender difference.

Stress-induced hyperthermia was determined by a second measurement of rectal temperature (T2) 3 min after recording of T1 and expressed as the difference T2 − T1. At this second measurement, the rectal temperature (T2) did not exhibit any gender- and treatment-related differences (Fig. 9A). ANOVA of T (Fig. 9B) revealed that this parameter was gender-dependent (F (1,37) = 52.44, P < 0.01) and that there was an interaction between gender and iodoacetamide treatment (F (1,37) = 18.01, P < 0.01). T was significantly larger in male control mice than in female control mice (Tukey HSD test: P < 0.01; Fig. 9B). Iodoacetamide treatment enhanced T in female mice (Tukey HSD test: P < 0.01) and reduced it in male mice (Tukey HSD test: P < 0.05) so that T no longer differed between male and female animals (Fig. 9B).

Relationship between estrous cycle, anxiety-related behavior and corticosterone levels

Pilot experiments involving 30 female mice housed in groups of three revealed that the estrous cycle was largely synchronized among the 10 cages under study. Thus, 24 of the 30 mice were found to be in the estrus stage on a given day. In the proper experiments, another cohort of 30 female mice was divided into six groups of five mice each, each group being tested on the EPMT on six consecutive days. Due to irregularities in cycling, 16 mice were found to be in the estrus phase, while eight, four and four mice were in the metestrus, proestrus and diestrus phase, respectively, at the time of testing. Because of this imbalance in the distribution of the different estrous cycle phases, the data obtained in the met-, pro- and diestrus stages were pooled in a common group termed nonestrus phase. There was no significant correlation between the time spent on the open arms and the estrus and nonestrus phase (Table 1).

The same result was found when, after a pause of more than 1 week, the relationship between estrous cycle phase and circulating corticosterone at baseline and following stress exposure was examined. After measuring baseline levels of corticosterone, the animals were subjected to restraint stress for 10 min, and corticosterone levels were measured 45 min after the onset of restraint stress. As shown in Table 1, there was no significant correlation of the estrus and nonestrus phase with baseline as well as stress-induced corticosterone levels (Table 1).

Effect of iodoacetamide treatment on stress-coping behavior in the TST

The time of immobility during a 6 min test period was assessed as a measure of depression-like behavior and expressed as a percentage of the test duration. Male and female control mice did not differ in the relative time of immobility, and this parameter was not altered by iodoacetamide treatment (Table 2).

DISCUSSION

In view of the emerging evidence that anxiety and depression are factors relevant to both IBD and pain-related bowel disorders (Mayer and Collins, 2002; Whitehead et al., 2002; Spiller, 2003; Mawdsley and Rampton, 2005;...
the overall aim of the present study was to test for a possible relationship between gastric inflammation and anxiety- and depression-related behavior in mice. While it has previously been shown that experimentally induced depression- and anxiety-like phenotypes enhance the vulnerability to intestinal inflammation (Varghese et al., 2006) and lead to colonic hypersensitivity (Bradesi et al., 2005; Myers et al., 2005), it has not yet been explored whether gastrointestinal inflammation has an impact on affective behavior. The results of the current study show that experimentally induced gastritis causes behavioral alterations indicative of enhanced anxiety but does not change stress-coping and depression-related behavior.

The behavioral reactions to experimental gastritis were studied here for two reasons. Firstly, there is clinical evidence for a comorbidity of functional dyspepsia with anxiety. Experimentally induced anxiety in human volunteers decreases gastric compliance and lowers the intragastric volume that induces discomfort (Geeraerts et al., 2005). Both types of alterations are also found in patients with functional dyspepsia (Tack et al., 2004), in which both anxiolytic and antidepressant treatment has a beneficial effect (Hojo et al., 2005). Secondly, iodoacetamide-induced gastritis in rats is associated with hypersensitivity to both mechanical and chemical noxious stimulation of the stomach. As a result, iodoacetamide-induced gastritis has been proposed to represent an experimental model of dyspepsia (Ozaki et al., 2002; Lamb et al., 2003).

Iodoacetamide was added to the drinking water at a concentration of 0.1% for 7 days, which has been shown to elicit murine gastritis (Piqueras et al., 2003) as confirmed by a significant increase in MPO activity in the gastric wall. This parameter reflects inflammation-associated infiltration of neutrophils and monocytes into the tissue (Suzuki et al., 1983; Krawisz et al., 1984; Graff et al., 1998) and is consistent with the iodoacetamide-induced infiltration of inflammatory cells and histological indices of inflammation in the gastric mucosa and submucosa (Piqueras et al., 2003; Takeeda et al., 2004). Although immune cells could be seen in the mucosa and submucosa of iodoacetamide-pretreated Swiss CD-1 mice (Piqueras et al., 2003), the rise of MPO activity which iodoacetamide treatment caused in the stomach of Him:OF mice was apparently too moderate to be seen as an appreciable accumulation of immune cells by routine histology. The effect of iodoacetamide to cause mild injury to the gastric surface epithelium (Holzer et al., 2007) was confirmed in the present study which, in addition, revealed that the adverse effect of iodoacetamide was confined to the stomach but did not involve the mucosa of the small and large intestine.
A potential drawback of the iodoacetamide gastritis model is the significant reduction of water intake that occurs if iodoacetamide is added to the drinking water, which along with a reduction of body weight has been noted previously (Ozaki et al., 2002; Piqueras et al., 2003; Holzer et al., 2007). Analysis of the circadian activity patterns revealed that iodoacetamide reduced drinking and feeding only during the dark phase to a significant extent. This observation suggests that the reduction of water intake is not primarily taste-related but, together with the decrease in feeding and locomotor activity, reflects a behavioral consequence of gastritis. We base this argument on the premise that a reduction of locomotor activity, feeding and drinking is a characteristic of sickness behavior (Goehler et al., 2000; Konsman et al., 2002). Since water intake, expressed as ml per g body weight, was practically identical in either gender, the dosing of iodoacetamide per g body weight must have been similar in male and female mice. Thus, differences in iodoacetamide intake cannot account for the gender-related alterations in MPO, corticosterone and anxiety scores measured after a 7 day period of iodoacetamide treatment.

Since pain-related bowel disorders have a higher prevalence in women than in men (Strid et al., 2001; Chang and Heitkemper, 2002; Taché et al., 2005), we used both male and female mice to test for gender differences in the possible impact of gastric inflammation on affective behavior. Indeed, gender-dependent differences in the severity of iodoacetamide-induced gastritis and its effect on circulating corticosterone, body temperature and anxiety were observed. Although the estrous cycle of the female mice in these experiments was not determined, it is unlikely that our data were significantly influenced by this factor, because the results obtained from male and female mice did not differ in the coefficient of variation. This inference was confirmed by the observation that the anxiety-related behavior on the EPMT and the levels of circulating corticosterone, body temperature and anxiety were observed. Although the estrous cycle of the female mice in these experiments was not determined, it is unlikely that our data were significantly influenced by this factor, because the results obtained from male and female mice did not differ in the coefficient of variation. This inference was confirmed by the observation that the anxiety-related behavior on the EPMT and the levels of circulating corticosterone at baseline and following restraint stress did not differ between mice in the oestrous stage and those in the nonestrous stage. We conclude, therefore, that the gastritis-associated changes in these parameters among female mice do not reflect fluctuations of female sex steroids during the estrous cycle. Whether long-term effects of estrogen determine the gender-related effects of iodoacetamide-induced gastritis remains to be investigated.

Treatment of mice with iodoacetamide for 1 week enhanced gastric MPO activity, the increase in female mice being significantly larger than that in male mice. It appears, therefore, that female mice are more vulnerable to iodoacetamide-evoked gastritis than male mice. This gender difference disappeared after the mice had been subjected to behavioral testing over the next 4 days, as gastric MPO activity in iodoacetamide-treated female mice fell to that seen in male iodoacetamide-treated mice. Whether this anti-inflammatory effect is related to the behavioral test procedure or reflects habituation to the exaggerated inflammatory reaction in female mice cannot be deduced from the present results. In contrast, the behavioral test procedure which is inherently stressful caused a non-significant rise of gastric MPO activity in the control mice, which is reminiscent of the ability of stress to adversely

![Fig. 8. Behavior of control and iodoacetamide-treated mice of either gender in the EPMT, performed on day 15 in the course of the experiments. The animals drank either normal tap water (control) or tap water containing iodoacetamide (0.1%) from experimental day 8 onwards. The graphs show the time spent on the open arms (A), the number of their entries into the open arms (B), and the total distance traveled in the open and closed arms (C) during the 5 min test session. The values represent means ± S.E.M., n as indicated in brackets. * P<0.05 versus control mice of the same gender; ** P<0.01 versus male control mice.](image)
affect gastrointestinal mucosal function in normal rodents (Taché and Perdue, 2004).

Female mice with iodoacetamide-induced gastritis exhibited enhanced anxiety-related behavior as assessed in the EPMT (Pellow and File, 1986; Belzung and Griebel, 2001). Iodoacetamide treatment reduced both the number of entries into the open arms and the time spent on the open arms in female, but not male mice. Although it could be argued that iodoacetamide treatment failed to reduce the time that male mice moved on the open arms, because male control mice spent significantly less time on the open arms than female control mice, this argument is not applicable to the number of open arm entries in which male and female control mice did not significantly differ. In addition, iodoacetamide treatment failed to significantly attenuate the overall locomotor activity of male and female mice in the EPMT, which is in keeping with the finding that home-cage activity did not change during the light phase. We conclude, therefore, that experimental gastritis has an anxiogenic effect in female, but not male, mice and relate this gender difference to the severity of gastritis which was greater in female than in male animals.

The gender-related increase in anxiety due to gastritis went in parallel with a decrease in the basal levels of circulating corticosterone, which is likely to reflect reduced activity in the HPA axis (Engelmann et al., 2004). The observation that the iodoacetamide-induced fall in circulating corticosterone was seen only under basal conditions, but not after exposure to the stressful TST, argues against a down-regulation of the HPA axis. Since repeated stress is known to increase trait anxiety (Chotiwat and Harris, 2006), prolonged gastritis could be viewed as an internal stressor that enhances anxiety-like behavior and causes habituation of the HPA axis (Armario et al., 2004) in a gender-dependent manner. Since iodoacetamide does not enter the brain to any appreciable degree, as visualized by

---

**Table 1.** Lack of correlation between estrus phase and anxiety as well as circulating corticosterone at baseline and following restraint stress

<table>
<thead>
<tr>
<th>Parameter under study</th>
<th>Estrus</th>
<th>Nonestrus</th>
<th>Correlation coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time spent on open arms (EPMT)</td>
<td>9.0 ± 2.1% (16)</td>
<td>10.5 ± 2.8% (14)</td>
<td>-0.0540</td>
</tr>
<tr>
<td>Circulating corticosterone at baseline</td>
<td>50.3 ± 10.4 ng/ml (12)</td>
<td>45.2 ± 7.5 ng/ml (18)</td>
<td>0.0765</td>
</tr>
<tr>
<td>Circulating corticosterone after restraint stress</td>
<td>97.5 ± 17.4 ng/ml (12)</td>
<td>102.4 ± 16.1 ng/ml (18)</td>
<td>0.0118</td>
</tr>
</tbody>
</table>

Thirty female mice were distributed to six groups of five mice each. Groupwise testing of the animals on the EPMT and collecting blood before and after stress on consecutive days allowed for analysis of the relationship between estrus phase and anxiety as well as circulating corticosterone. There was no significant correlation of the time spent on the open arms in the EPMT (expressed as a percentage of the total time spent on any arm during the 5 min test session) and the circulating corticosterone levels (measured before and 45 min after the onset of a 10 min exposure to restraint stress) with the estrous cycle. The nonestrus stage comprises the met-, pro- and diestrus phases. The values represent means ± S.E.M., n as indicated in brackets.
Table 2. Time of immobility in control and iodoacetamid-treated mice of either gender subjected to the TST

<table>
<thead>
<tr>
<th>Gender</th>
<th>Treatment</th>
<th>Time of immobility (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>Control</td>
<td>29.2 ± 2.5 (7)</td>
</tr>
<tr>
<td>Female</td>
<td>Iodoacetamide</td>
<td>24.0 ± 4.6 (10)</td>
</tr>
<tr>
<td>Male</td>
<td>Control</td>
<td>27.2 ± 5.3 (10)</td>
</tr>
<tr>
<td>Male</td>
<td>Iodoacetamide</td>
<td>27.0 ± 4.1 (11)</td>
</tr>
</tbody>
</table>

The animals drank either normal tap water (control) or tap water containing iodoacetamide (0.1%) from experimental day 8 onwards; they were subjected to the TST on day 18 in the course of the experiments. In this test, the time of immobility was assessed during a 6 min observation period and expressed as a percentage of the total test duration. The values represent means ± S.E.M., n as indicated in brackets. There was no significant gender and treatment effect. The number of animals in the female control group was only seven, because three female control mice escaped from the force displacement transducer during the test procedure.

SPECT, we conclude that the effects of iodoacetamide on trait anxiety and HPA axis activity are brought about by a peripheral site of action, most likely as a consequence of low-grade gastritis. Gastritis may be signaled to the brain via hypersensitivity of afferent nerve pathways (Lamb et al., 2003; Holzer et al., 2007) or via endocrine routes involving proinflammatory cytokines (Turnbull and Rivier, 1999). It can at present not be ruled out that disturbances in fluid, electrolyte and hormonal homeostasis, resulting from decreased intake of water and food, may also contribute to the iodoacetamide-induced alterations of brain functions.

Our finding of reduced corticosterone levels in female mice suffering from low-grade gastritis is in line with a report that basal cortisol levels in the saliva of patients with functional dyspepsia or irritable bowel syndrome are lower than in healthy controls (Bohmelt et al., 2005). In addition, our experimental approach takes account of the emerging association of functional gastrointestinal disorders with low-grade inflammation, increased anxiety and female gender (Wilhelmsen et al., 1995; Mayer et al., 2001a; Strid et al., 2001; Chang and Heitkemper, 2002; Whitehead et al., 2002; Dunlop et al., 2003; Tomblom et al., 2005; Talley, 2006). The ability of iodoacetamide to induce gastric hyperalgesia (Lamb et al., 2003; Holzer et al., 2007) and to cause low-grade gastric inflammation, enhance trait anxiety and lower circulating corticosterone levels in a gender-related manner (this study) reproduces several aspects of pain-related bowel disorders with a remarkable degree of face validity.

Relative to the EPMT, the SIHT has the advantage of assessing anxiety phenotypes in a locomotion-independent manner (Zethof et al., 1994; Olivier et al., 2003). In the present study, however, this test was complicated by gender-dependent differences in the T1 and treatment-induced changes of T1. While T1 in male control mice was significantly lower than that of female control mice, iodoacetamide treatment decreased T1 in female mice and increased it in male mice so that T1 was no longer different between the two genders. The effect of iodoacetamide-induced gastritis on body temperature points to complex thermoregulatory changes associated with gastrointestinal pathology. Stress-induced hyperthermia (ΔT) is thought to be a homeostatic reaction that involves the central as well as sympathetic nervous system (Oka et al., 2001; Liu et al., 2003; DiMicco et al., 2006). In the present study it was found that iodoacetamide treatment enhanced ΔT in female and reduced it in male mice, relative to ΔT seen in control animals. We think, however, that this observation cannot be interpreted as evidence for gastritis-induced anxiety in female mice, because both T1 and ΔT were subject to complex gender- and treatment-related differences and T2 was independent of gender and treatment. Thus, ΔT in female control mice may have been cut short by a ceiling effect, given that T1 was highest in these animals. As a result, we propose that the SIHT can be used to assess anxiety only if T1 is not affected by gender and experimental manipulation.

Depression-like behavior was evaluated with the TST which measures the stress-coping ability of the animals (Steru et al., 1985; Liu and Gershensonfeld, 2001; Cryan et al., 2005). As iodoacetamide treatment failed to alter the relative time of immobility in this test in both male and female mice (Table 2), we conclude that experimental gastritis does not induce behavioral changes indicative of depression. This inference is backed by the observation that the TST-evoked elevation of circulating corticosterone was similar in control and iodoacetamide-treated animals. It is known that, after exposure of mice to a stressful situation, circulating corticosterone rises to a maximum within 10–20 min and subsequently wanes due to corticosterone-mediated feedback inhibition of the release of corticotropin-releasing factor and adrenocorticotropic hormone (Müller et al., 2003; Oshima et al., 2003). In view of these dynamics of the HPA axis we infer that stress-induced activation and feedback inhibition of the HPA axis was not altered by iodoacetamide treatment, whereas depression is known to be associated with elevated levels of circulating corticosterone, or cortisol in humans, due to impaired feedback inhibition of the HPA axis (Holsboer, 2000; Cryan and Mombereau, 2004).

CONCLUSION

In summary, we have shown that iodoacetamide treatment induces gastritis in a gender-related manner, its severity being significantly greater in female than in male mice. The induction of exaggerated gastritis in female mice is associated with a reduction of circulating corticosterone and body temperature and an enforcement of behavioral indices of anxiety. Gastric inflammation thus has a gender-dependent influence on emotional-affective behavior and its neuroendocrine regulation. In a wider perspective, our findings suggest that not only stress and psychiatric disorders can give rise to functional disturbances of the gut but that gastrointestinal pathology also can impact on the CNS to affect mood and its neuroendocrine control.

Acknowledgments—This study was supported by the Zukunftsfonds Steiermark (grant 262), the Austrian Scientific Research Funds (FWF grant L25-B05) and a scholarship grant of the Inter-
disciplinary Centre for Clinical Research at the University of Würzburg (M.C.K.). The authors thank Dr. Michael Trappitsch (Graz) for his invaluable help in the development of the TST software and Dr. Adelheid Kresse (Graz) for her advice on the analysis of the estrous cycle. The support by the director and staff of the Center for Medical Research (ZMF I) of the Medical University of Graz is also greatly appreciated.

REFERENCES


(Accepted 17 September 2007) (Available online 18 September 2007)